Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jiří Hak"'
Publikováno v:
Acta Medica, Vol 55, Iss 2, Pp 78-82 (2012)
The incidence of venous thromboembolism (VTE) during childhood is low with two peaks – neonatal and adolescent age. This retrospective study is focused on clinical characteristics of VTE during adolescence. The main goals are to assess the most fre
Externí odkaz:
https://doaj.org/article/4dc31008d7d54588b0d24efa36998781
Publikováno v:
Acta Medica, Vol 40, Iss 2, Pp 51-56 (1997)
The most frequent ocular findings in acute leukemia cases of children and two of our own observations are presented in this study. Emphasized are all difficulties in fixing the diagnosis and the necessity of close cooperation between ophthalmologist,
Externí odkaz:
https://doaj.org/article/d0296d3aa90245009ac6bb52916180cd
Autor:
Kateřina, Zdráhalová, Jaroslav, Štěrba, Jiří, Domanský, Bohumír, Blažek, Hana, Ptoszková, Vladimír, Mihál, Zbyněk, Novák, Jiří, Hak, Daniela, Procházková, Zdena, Černá, Pavel, Timr, Yahia, Jabali, Petr, Sedláček, Petr, Smíšek, Zuzana, Zemanová, Marie, Jarošová, Alena, Houdková, Ester, Mejstříková, Ondřej, Hrušák, Jan, Zuna, Iveta, Janotová, Jan, Trka, Jan, Starý
Publikováno v:
Casopis lekaru ceskych. 154(2)
Acute lymphoblastic leukemia (ALL) is the most frequent childhood malignancy. Treatment has been unified in the middle of 1980 in the Czech Republic. In 2002-2007 children and adolescents with acute lymphoblastic leukemia were treated in an internati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::db644176826787d2adf73ae442860f27
https://pubmed.ncbi.nlm.nih.gov/25994910
https://pubmed.ncbi.nlm.nih.gov/25994910
Publikováno v:
Acta Medica, Vol 40, Iss 2, Pp 51-56 (1997)
Scopus-Elsevier
Scopus-Elsevier
The most frequent ocular findings in acute leukemia cases of children and two of our own observations are presented in this study. Emphasized are all difficulties in fixing the diagnosis and the necessity of close cooperation between ophthalmologist,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd67d2d7649b7f28f68ad2fe6857b41a
https://pubmed.ncbi.nlm.nih.gov/9389212
https://pubmed.ncbi.nlm.nih.gov/9389212
Publikováno v:
ResearcherID
The present study evaluated the pharmacokinetics of methotrexate (MTX, CAS 59-05-2) and 7-hydroxymethotrexate (7-OHMTX, CAS 5939-37-7) in children with acute lymphoblastic leukemia (ALL) with particular interest devoted to the renal excretion at the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9daa85d0decb7dd1b7eeb4ceb6b0a7
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000285797400005&KeyUID=WOS:000285797400005
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000285797400005&KeyUID=WOS:000285797400005
Autor:
Jana Volejnikova, Ester Mejstrikova, Tatana Valova, Leona Reznickova, Ladislava Hodonska, Vladimir Mihal, Jaroslav Sterba, Yahia Jabali, Daniela Prochazkova, Bohumir Blazek, Jiri Hak, Zdenka Cerna, Ondrej Hrusak, Jan Stary, Jan Trka, Eva Fronkova
Publikováno v:
Haematologica, Vol 96, Iss 12 (2011)
Background Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone mar
Externí odkaz:
https://doaj.org/article/56f8f534185b4b1abc8f07c8bc916afb
Autor:
Ester Mejstrikova, Jana Volejnikova, Eva Fronkova, Katerina Zdrahalova, Tomas Kalina, Jaroslav Sterba, Yahia Jabali, Vladimir Mihal, Bohumir Blazek, Zdena Cerna, Daniela Prochazkova, Jiri Hak, Zuzana Zemanova, Marie Jarosova, Alexandra Oltova, Petr Sedlacek, Jiri Schwarz, Jan Zuna, Jan Trka, Jan Stary, Ondrej Hrusak
Publikováno v:
Haematologica, Vol 95, Iss 6 (2010)
Background Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage marker
Externí odkaz:
https://doaj.org/article/00e3c2b1f9cb4fb2adcf9b49b33ebc86